Organic Active Ingredients TRIZ Cases

Topical PDE5 inhibition improves ocular perfusion in anterior ischemic optic neuropathy.

This case uses pyridine derivatives to inhibit MALT1, modulating NFKB signaling for resistant lymphoma and immune disorders.

This case uses benzoic or citric acid salts to formulate aqueous quetiapine at up to 5 mg/ml for predictable IV treatment.

This case shows how 1′-cyano nucleoside analogs target conserved viral polymerases across diverse virus families.

This case uses serum measurements and dosage titration to keep oral testosterone undecanoate within FDA-recommended ranges.

Optimized pH, buffers, and tonicity agents stabilize aqueous micafungin, reducing degradation, contamination risk, and compounding steps.

Folate-targeted TLR agonists reprogram M2 macrophages to support engineered cell therapy.

SHH concentration gradients establish anatomically positioned brain regions and precise neuronal connectivity in 3D culture.

This case uses macrocyclic compounds to selectively inhibit Factor XIa or plasma kallikrein for anticoagulation with less monitoring.

Ionizable lipidoids form nanoparticles that protect nucleic acids and support cellular uptake through pH-responsive endosomal release.

Photoactive aziridine compounds form complexes and covalent links with undruggable proteins, expanding targetable biology.

Forms A–I convert unstable amorphous material into crystalline drug substances with improved stability, solubility, filtration, and flow.

Substituted pyrimidinyl hydrazides block AHR signaling to counter tumor immune escape and support anti-tumor immunity.

This case combines AR antagonists, Finasteride, and gene disruption to eliminate resistant AML-initiating cells.

Explore pyrazolopyridine compounds that balance potent FGFR2 inhibition with selectivity against other FGFR isoforms.

A molecular glue uses substituted 4-aminoisoindoline to recruit CRL4CRBN for protein degradation.

This case uses systemic lipid nanoparticles to edit the liver TTR gene, enabling sustained protein reduction with acceptable biosafety.

A core-shell patch encapsulates drug within biodegradable shells and caps, delaying diffusion for controlled, long-term release.

A 10:2–10:4 SDP-to-FOS blend supports intestinal barriers, microbial balance, nutrient absorption, and lower pet food malodour.

EPCR-loaded stents pair limus drugs with endothelial protection to limit thrombosis risk.

This injectable hydrogel uses reversible aldehyde-amine crosslinks to retain lubrication and self-heal in biological media.

This case tunes monomer ratios, temperature, initiator concentration, and solvent crosslinking to improve polymer purity and stability.

This case uses a hemi-pamoate triazolone salt in dry-powder inhalation to maintain HNE inhibition and improve tolerability.

Stem-loops, pseudoknots, and guanosine quadruplexes extend RNA lifetime for more effective trans-splicing in human cells.

This case uses antibody-linker conjugates to deliver poorly permeable STING modulators into target cells and stimulate immunity.

This case uses tailored FXR agonist structures for intestinal uptake, activating local receptors while reducing systemic side effects.

A 3' UTR microRNA-targeted CVA21 genome reduces normal-tissue toxicity while maintaining oncolytic activity and faster viral rescue.

HPMC-based sustained-release Ca-AKG formulations reduce release spikes and support steadier plasma levels with less frequent dosing.

This case uses local dasatinib, tocotrienol, or quercetin to address senescence and extend AVF functionality and patency.

Polyacrylic acid, propylene glycol, and lactic acid ester balance skin absorption, formulation stability, and resistance to exudation.

Paraffin and silicone adhesive help stabilize rotigotine and improve patch adhesion.

This case addresses PARP inhibitor toxicity and form instability through PARP1-selective compounds and optimized acid salts and crystals.

An improved dispenser assembly controls droplet formation in liquid nitrogen to produce uniform pharmaceutical pellets and reduce clogging.

Antibody-drug conjugates with tunable phosphate linkers deliver glucocorticoids to target cells and reduce off-target toxicity.

This case uses a SHP2 ligand-linker-VHL ligand to trigger ubiquitination and reduce SHP2 levels for cancer treatment.

Formula (I) compounds inhibit LDHA and/or LDHB, improving solubility, permeability, and cancer-cell re-sensitization.

This case uses irreversible KRAS G12C binding to block downstream signaling and treat cancers with active brain metastases.

This case addresses linker complexity with phosphoalkyl ribose polymers that target tumor cells while limiting effects on healthy cells.

This case uses piperazine salt formation to pair water solubility with rapid onset, addressing fat-emulsion formulation risks.

Medium-chain triglycerides and suspending agents keep capecitabine homogeneous without vigorous shaking or water-driven degradation.

MAT2A inhibitors exploit MTAP loss to target cancer cells and limit harm to normal tissue.

Novel imidazole agonists target oral glucose control with reduced cardiotoxicity risk.

This case uses cereblon-binding piperidine diones to target AR signaling and address toxicity in resistant disease treatment.

This case uses lipid and amino acid surface treatment to stabilize OSA, limit polymerization, and support controlled skin delivery.

Controlled PLGA degradation and emulsification support uniform Lumateperone release from one week to two months, improving adherence.

This case combines fospropofol with pharmaceutically acceptable acids to improve oral absorption and reduce inter-subject variability.

Hydrogels and nanoparticles localize immunosuppressive agents around nerve allografts to support regeneration and reduce systemic risks.

This case shows how heparinoid additives preserve ascorbic acid composition stability by suppressing crystal formation during cold storage.

This case examines chiral N-1 branched cycloalkyl imidazoquinolines that induce cytokines for viral, tumor, and vaccine applications.

This case uses substituted hydantoinamides to selectively inhibit ADAMTS-7, addressing broad inhibition and inadequate therapeutic index.

Substituted pyrrolo[2,3-b]pyridine compounds inhibit CHK1 and CHK2 kinases to sensitize cancer cells while sparing normal cells.

Formula I bile acid derivatives modulate FXR and TGR5 receptors, addressing insufficient disease coverage of existing modulators.

Selective Formula I inhibitors target Factor XIa and plasma kallikrein to resolve insufficient thrombosis prevention in existing treatments.

Hydrophilic surfactants form micelles in a nimodipine parenteral solution, reducing ethanol content and adverse reactions while maintaining solubility.

Substituted benzothiazole compounds treat Huntington's disease by modulating mutant huntingtin protein aggregation.

Lactoferrin-derived peptides with disulfide bonds overcome slow endolysosomal release and immunogenicity in cell-penetrating peptide applications.

Segmenting aqueous ascorbic acid into droplets within a hydrophobic phase prevents rapid oxidation degradation while maintaining biological activity.

Gamma-glutamyl peptidase and alliinase convert precursors into S-alkenyl-L-cysteines, eliminating sulphoxides that cause gastrointestinal adverse effects.

Novel steroidal compounds induce androgen receptor degradation through structural modifications at C-3, C-16, and C-17 positions.

Segmentation and local quality resolve non-specific binding to inflamed tissues, improving diagnostic accuracy.

Anethole trithione inhibits tumor necrosis factor alpha secretion by macrophages to reduce arterial vessel contractility.

Glutarimides bind cereblon to alter substrate specificity, degrading intrinsic downstream proteins without requiring high cereblon expression levels.

An aqueous suspension of a small molecule therapeutic agent and organic acid enables sustained drug release while maintaining pH stability.

Amorphous sirolimus combined with fatty acid ester and polymer stabilizes the composition, reducing degradation while maintaining dissolution reliability.

Segmented bilayer tablets incorporate intragranular lubricants to resolve formulation complexity while maintaining dissolution rates for HIV treatment.

Sublingual cyclobenzaprine composition bypasses first-pass hepatic metabolism to deliver rapid transmucosal absorption.

Tetracyclic heteroaryl compounds bind G12C mutant Ras proteins, blocking uncontrolled cellular proliferation in cancers lacking approved inhibitors.

Combining anti-CEA CAR T cells with anti-CEA-IL2 immunocytokine recruits cells to solid tumors, overcoming trafficking limitations and inhibitory signals.

Algal oil carrier delivers peptides with protease inhibitors and chelating agents to overcome intestinal degradation and improve oral bioavailability.

Selective androgen receptor covalent antagonists irreversibly bind the N-terminal domain to inhibit proliferation.

A pharmaceutical composition combines hyaluronic acid with Actinidia chinensis and Zingiber officinale extracts to protect gastric tissue.

Identifying PALB2 mutations resolves diagnostic complexity by enabling targeted DNA-damaging agent therapy to improve survival rates.

Novel heterocyclic compound acts as EP4 receptor antagonist to inhibit IL-23 and IL-6 production.

A peptide-siRNA complex releases therapeutic RNA from endosomes in infected cells.

Nanoparticle-delivered miR-92a inhibitors reduce vascular stenosis and enhance arteriovenous fistula maturation.

A nicotinamide derivative increases plasma HDL cholesterol concentrations.

Gradual nalmefene escalation stabilizes mental state and minimizes adverse reactions while treating post-traumatic stress disorder.

Targeting PI3K delta inhibits TLR9-mediated immunopathology, resolving the trade-off between parasite clearance and severe inflammatory complications.

Agglomerate breakdown disperses active ingredients into primary particles, resolving adhesion and homogeneity contradictions in inhalation medicaments.

Segmented synthesis of a symmetrical diester intermediate enables selective hydrolysis to Clascoterone, reducing by-product formation and reaction time.

Hydrophobic lipid carriers suspend C21 in capsules, protecting the light-sensitive active ingredient from water degradation.

Aminaphtone reduces migraine pain intensity and prevents attacks without the serious adverse effects of conventional therapies.

Quinoxaline derivatives inhibit FGFR, VEGFR, and PDGFR kinases to prevent tumor growth in cancers with activating mutants.

Small molecule intermediaries bridge gp120 and anti-DNP antibodies, forming a ternary complex for immune destruction without expensive therapeutic antibodies.

Specific aminoindane structures directly inhibit NHE3, eliminating the delayed maximum effect of indirect squalamine inhibitors.

Pyrazolopyridazine compounds stabilize Clarin-1 protein function, addressing progressive hearing loss and retinal degeneration in Usher Syndrome.

Combining rilpivirine with chemotherapeutic agents reduces required drug dosage by up to 90% while minimizing side effects on normal cells.

Local quality customization of DFMO and NSAID regimens based on ODC1 genotypes minimizes ototoxicity while reducing advanced adenoma recurrence.

Novel tetrahydroisoquinoline structures resolve efficacy and specificity trade-offs by enhancing Nrf2 activity for treating oxidative stress disorders.

Non-aqueous solvent systems in dry-powder bendamustine formulations minimize hydrolysis degradation and impurity formation during storage and reconstitution.

Pyrazolo[1,5-a]pyrimidine derivatives inhibit MK2 to lower cytokine production while minimizing off-target kinase interactions.

Nanoscale calcipotriol crystals improve skin penetration without propylene glycol, reducing irritation while maintaining efficacy.

A novel immunosuppressant compound reduces immune activation and inflammatory cytokine infiltration without nephrotoxicity.

Polysaccharide and oil composition restores immune surveillance by increasing effector cells while decreasing VEGF expression to treat tumors.

Cationic polymer complexes electrostatically bind mRNA encoding follistatin to promote lean muscle mass growth.

Antisense oligonucleotides degrade PTP1B mRNA to overcome limited efficacy of small molecule inhibitors.

Continuous homogenization of the solution stabilizes particle size between 50 and 700 nm, preventing aggregation while maintaining bioavailability.

Segmenting candesartan and amlodipine into distinct granulate and extragranular phases prevents chemical incompatibility while preserving therapeutic efficacy.

Daily oral (R)-silodosin induces reversible aspermia via alpha-1-adrenoreceptor antagonism, avoiding hormonal side effects.

A transport-promoting molecular dispersant enables stable adhesion of antirestenotic agents on balloon catheters.

Spiro-oxazolones modulate V1a receptors to treat anxiety and depression while avoiding blood homeostasis side effects.

3-indolyl furanoid compounds inhibit matrix metalloproteinase-9 expression in gastric mucosal tissue.

Segmented synthesis eliminates microwave heating and column purification, enabling mass production of high-purity tankyrase inhibitors.

Alogliptin gel capsule formulation uses croscarmellose sodium to enhance solubility while maintaining content uniformity during manufacturing.

Small molecule 2,5-diazabicyclo[4.2.0]octanes replace injectable peptides to improve oral bioavailability and patient compliance.

A 5-deazaflavin compound acts as a redox catalyst to activate intracellular ATP production in mitochondria.

Targeting the P2Y2 receptor pathway reduces platelet-mediated tumour cell transmigration, addressing ineffective metastasis prevention.

Combines chemical chaperones and kinase inhibitors to address protein misfolding in neurodegenerative disorders.

Trinucleotide cap analogs prevent reverse orientation and guanine competition during in vitro transcription, ensuring proper 5' capping.

Specific small molecule inhibitors target APOL1 pore formation to control disease progression without severe side effects from broad immunosuppression.

Heteroaromatic phenylimidazole derivatives inhibit PDE10A enzyme activity, resolving metabolic stability and bioavailability trade-offs in long-term treatment.

Thickening agents adjust aqueous solution viscosity to 10-30 mPa·s, preventing precipitation of 8-oxo-2'-deoxyguanosine during storage.

Iron-chelating compositions induce reactive oxygen species to kill cancer stem cells and prevent relapse.

Administers PD-1 antibody and FGFR inhibitor combination therapy to address lack of options for patients with FGFR alterations.

Formula I compound merges neuroprotection with neurite outgrowth to restore neural information transfer.

Heat-inactivated probiotics preserve anti-inflammatory efficacy while extending shelf-life and eliminating adverse reaction risks in vulnerable infants.

Administering IL-2 pathway inhibitors prevents immune responses that compromise pharmacokinetic data accuracy in non-human primate studies.

Injectable thermosensitive hydrogel creates a localized tumor depot to inhibit growth and metastasis while minimizing systemic side effects.

Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine merges with non-steroidal anti-inflammatory drugs to target inflammatory pathways.

Fumaric acid buffers pH above 4.5 to prevent decomposition of nonpeptidic active ingredients under varying storage conditions.

Segmented ddRNAi agents reduce viral load and prevent resistance by targeting multiple distinct genome regions simultaneously.

CBI CC-1065 analogs replace CPI units with CBI moieties to reduce systemic toxicity while maintaining antitumor activity.